Handelsbanken Fonder AB Acquires Shares of 18,600 Kodiak Sciences Inc. $KOD

Handelsbanken Fonder AB bought a new position in shares of Kodiak Sciences Inc. (NASDAQ:KOD) in the 2nd quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The institutional investor bought 18,600 shares of the company’s stock, valued at approximately $725,000.

Other large investors have also recently modified their holdings of the company. Bank of America Corp DE increased its stake in shares of Kodiak Sciences by 52.7% in the 1st quarter. Bank of America Corp DE now owns 300,356 shares of the company’s stock valued at $11,450,000 after purchasing an additional 103,667 shares during the last quarter. Janus Henderson Group PLC raised its holdings in shares of Kodiak Sciences by 32.5% during the 1st quarter. Janus Henderson Group PLC now owns 1,325,457 shares of the company’s stock worth $50,540,000 after buying an additional 325,457 shares in the last quarter. EverSource Wealth Advisors LLC lifted its position in shares of Kodiak Sciences by 94.5% during the 1st quarter. EverSource Wealth Advisors LLC now owns 1,927 shares of the company’s stock worth $73,000 after buying an additional 936 shares during the last quarter. California State Teachers Retirement System lifted its position in shares of Kodiak Sciences by 1,358.9% during the 1st quarter. California State Teachers Retirement System now owns 29,396 shares of the company’s stock worth $1,121,000 after buying an additional 27,381 shares during the last quarter. Finally, The Manufacturers Life Insurance Company boosted its stake in Kodiak Sciences by 31.8% in the first quarter. The Manufacturers Life Insurance Company now owns 120,629 shares of the company’s stock valued at $4,598,000 after buying an additional 29,121 shares in the last quarter. Institutional investors and hedge funds own 89.06% of the company’s stock.

Key Stories Impacting Kodiak Sciences

Here are the key news stories impacting Kodiak Sciences this week:

• Positive Sentiment: HC Wainwright reiterated its Buy rating and maintained a $58 price target, implying substantial potential upside from recent levels. Kodiak was also highlighted among healthcare stocks viewed favorably by analysts. HC Wainwright Reiterates Buy Rating for Kodiak Sciences Analysts Are Bullish on These Healthcare Stocks
• Neutral Sentiment: The bullish rating reflects confidence in Kodiak’s longer-term outlook, with HC Wainwright modeling a shift from losses to profitability by 2029 and stronger earnings by 2030. However, these forecasts remain several years out and depend on the company’s development and commercialization plans.
• Negative Sentiment: HC Wainwright lowered its EPS forecasts across 2026–2030. Estimates were reduced to losses of $3.75 per share for 2026, $3.27 for 2027, and $2.01 for 2028; projected profits for 2029 and 2030 were also cut to $0.18 and $3.04, respectively. Quarterly loss estimates for the third and fourth quarters of 2026 were reduced to $0.89 per share. The revisions indicate higher expected losses and a weaker long-term earnings trajectory, which may be weighing on sentiment.

Wall Street Analysts Forecast Growth

A number of research firms have issued reports on KOD. Wall Street Zen cut Kodiak Sciences from a “hold” rating to a “sell” rating in a research report on Saturday, August 15th. Weiss Ratings reissued a “sell (d-)” rating on shares of Kodiak Sciences in a report on Friday, July 10th. JPMorgan Chase & Co. raised their price target on shares of Kodiak Sciences from $56.00 to $66.00 and gave the company an “overweight” rating in a research note on Monday, August 3rd. HC Wainwright reaffirmed a “buy” rating and set a $58.00 price target on shares of Kodiak Sciences in a report on Monday. Finally, Chardan Capital raised shares of Kodiak Sciences from a “neutral” rating to a “buy” rating and lifted their price target for the company from $14.00 to $61.00 in a report on Monday, May 11th. Six research analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has issued a Sell rating to the stock. According to MarketBeat, Kodiak Sciences presently has a consensus rating of “Moderate Buy” and a consensus target price of $48.14.

Kodiak Sciences Stock Performance

Shares of KOD opened at $39.84 on Friday. Kodiak Sciences Inc. has a 52 week low of $8.29 and a 52 week high of $47.84. The stock has a market capitalization of $2.50 billion, a price-to-earnings ratio of -9.51 and a beta of 2.21. The stock has a fifty day moving average of $39.81 and a 200-day moving average of $35.45.

Kodiak Sciences (NASDAQ:KOD) last released its quarterly earnings data on Wednesday, August 12th. The company reported ($1.05) earnings per share for the quarter, missing the consensus estimate of ($0.96) by ($0.09). As a group, equities analysts forecast that Kodiak Sciences Inc. will post -3.83 EPS for the current year.

Kodiak Sciences Company Profile

Kodiak Sciences, Inc is a clinical?stage biopharmaceutical company headquartered in Palo Alto, California, that focuses on the discovery and development of novel therapies for retinal diseases. The company’s proprietary technology centers on antibody biopolymer conjugates (ABCs), which are designed to extend durability, enhance tissue penetration and improve the safety profile of existing therapeutic modalities. Kodiak’s research and development efforts target conditions such as wet age-related macular degeneration (wet AMD), diabetic macular edema (DME) and other serious ophthalmic disorders.

The lead product candidate in Kodiak’s pipeline is KSI-301, an anti-VEGF antibody biopolymer conjugate administered via intravitreal injection.